Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background And Aims: Health systems struggle to deliver guideline-recommended multidisciplinary care to patients with irritable bowel syndrome (IBS). Digital collaborative care models (DCCMs) that integrate technology with experienced providers offer a promising solution for improving IBS management. We aimed to evaluate whether a novel DCCM improved clinical outcomes in IBS.

Methods: A prospective, longitudinal uncontrolled single-arm study design was used to assess the Ayble Health program. Participants were recruited online via social media, clinic, or employer. Data were prospectively collected from 202 participants (78% female; 78% white) with active IBS symptoms at baseline (≥ 75 on the IBS symptom severity scale (IBS-SSS)) and completed at least one follow-up symptom survey. All participants engaged in at least one care pathway: (1) a multidisciplinary care team, (2) a nutrition program with a personalized elimination diet, and (3) a brain-gut behavioral therapy (BGBT) program. Each pathway was supported by AI algorithms trained on a large, multimodal GI dataset to identify and communicate key trends in patient-reported outcomes, further personalizing care plans.

Results: Of the 202 participants, 197 (98%) participated in the nutrition pathway, 152 (75%) the BGBT pathway, and 156 (77%) the care team pathway. The majority of participants (62%) enrolled in all three pathways. Participants experienced a 140-point decrease in IBS-SSS, on average, with 86% experiencing a ≥ 50-point reduction.

Conclusion: The novel DCCM successfully delivered evidence-based care to participants with active IBS symptoms, with clinically significant, sustained symptom relief. Randomized clinical trials are recommended to assess cost and treatment efficacy compared to standard of care approaches.

Download full-text PDF

Source
http://dx.doi.org/10.1111/nmo.70144DOI Listing

Publication Analysis

Top Keywords

ibs symptoms
12
care
9
digital collaborative
8
collaborative care
8
multidisciplinary care
8
novel dccm
8
202 participants
8
active ibs
8
care team
8
participants
7

Similar Publications

Background: Anti-integrin αvβ6 IgG autoantibodies showed good sensitivity and optimal specificity in ulcerative colitis (UC) compared to controls. We aim at confirming the diagnostic accuracy of anti-integrin αvβ6 autoantibodies in an Italian multicentric cohort.

Methods: This observational multicentric study included adult and pediatric patients with inflammatory bowel disease and controls.

View Article and Find Full Text PDF

Performance comparison of germline variant calling tools in sporadic disease cohorts.

Mol Genet Genomics

September 2025

Human Phenome Institute, MOE Key Laboratory of Contemporary Anthropology, Zhangjiang Fudan International Innovation Center, Fudan University, 825 Zhangheng Road, Shanghai, 201203, China.

Accurate variant calling is essential for next-generation sequencing (NGS)-based diagnosis of rare diseases, yet most benchmarking studies have focused on standard cell lines or trio-based samples, with limited relevance to sporadic cases. Here, we systematically compared the performance of DeepVariant and GATK HaplotypeCaller in two Chinese cohorts of patients with sporadic epilepsy (EP) and autism spectrum disorder (ASD). DeepVariant exhibited higher precision and sensitivity in detecting single nucleotide variants (SNVs), while GATK showed a distinct advantage in identifying rare variants, which are often key to understanding the genetic basis of rare diseases.

View Article and Find Full Text PDF

Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with a largely unknown duration and pathophysiology of the pre-diagnostic phase, especially for the common non-monogenic form.

Methods: We leveraged the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort with up to 30 years of follow-up to identify incident ALS cases across five European countries. Pre-diagnostic plasma samples from initially healthy participants underwent high-throughput proteomic profiling (7,285 protein markers, SomaScan).

View Article and Find Full Text PDF

Background And Aims: Health systems struggle to deliver guideline-recommended multidisciplinary care to patients with irritable bowel syndrome (IBS). Digital collaborative care models (DCCMs) that integrate technology with experienced providers offer a promising solution for improving IBS management. We aimed to evaluate whether a novel DCCM improved clinical outcomes in IBS.

View Article and Find Full Text PDF

C1 inhibitor: from complement system to bradykinin angioedema.

Curr Opin Immunol

September 2025

Univ. Grenoble Alpes, CNRS, CEA, UMR5075, IBS, Laboratoire d'Immunologie, CHU Grenoble Alpes, 38000 Grenoble, France.

C1 Inhibitor (C1INH) is a crucial regulator of multiple plasmatic pathways, including complement, coagulation, kallikrein-kinin systems, and fibrinolysis. C1INH deficiency results in the downstream overproduction of the vasoactive peptide bradykinin (BK), the primary mediator of angioedema (AE), a rare disease characterized by unpredictable attacks of swelling in various locations of the body. C1INH deficiency can be hereditary (caused by a mutation in SERPING1 gene) or acquired (frequently underlying lymphoproliferative disease); C1INH level and functional assays are the golden standard for biological diagnosis of C1INH deficiency.

View Article and Find Full Text PDF